Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MN-001 in NAFLD, T2DM, and Hypertriglyceridemia
NCT05464784Phase 2Active, not recruiting
- Sponsor
- MediciNova, Inc.
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipelukast in non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), hypertriglyceridemia, sponsored by MediciNova, Inc.. Started Aug 2022; status: active, not recruiting.
02
Drugs
tipelukast
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)hypertriglyceridemia
Beyond the preview
Go deeper on NCT05464784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464784.